Afficher la notice abrégée

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

dc.rights.licenseopenen_US
dc.contributor.authorTORREGROSA, Cecile
dc.contributor.authorPERNOT, Simon
dc.contributor.authorVAFLARD, Pauline
dc.contributor.authorPERRET, Audrey
dc.contributor.authorTOURNIGAND, Christophe
dc.contributor.authorRANDRIAN, Violaine
dc.contributor.authorDOAT, Solene
dc.contributor.authorNEUZILLET, Cindy
dc.contributor.authorMOULIN, Valerie
dc.contributor.authorSTOUVENOT, Morgane
dc.contributor.authorROTH, Gael
dc.contributor.authorDARBAS, Tiffany
dc.contributor.authorAUBERGER, Benjamin
dc.contributor.authorGODET, Tiphaine
dc.contributor.authorJAFFRELOT, Marion
dc.contributor.authorLAMBERT, Aurelien
dc.contributor.authorDUBREUIL, Olivier
dc.contributor.authorGLUSZAK, Cassandre
dc.contributor.authorBERNARD-TESSIER, Alice
dc.contributor.authorTURPIN, Anthony
dc.contributor.authorPALMIERI, Lola-Jade
dc.contributor.authorBOUCHE, Olivier
dc.contributor.authorGOUJON, Gael
dc.contributor.authorLECOMTE, Thierry
dc.contributor.authorSEFRIOUI, David
dc.contributor.authorLOCHER, Christophe
dc.contributor.authorGRADOS, Lucien
dc.contributor.authorGIGNOUX, Pauline
dc.contributor.authorTRAGER, Stephanie
dc.contributor.authorNASSIF, Elise
dc.contributor.authorSAINT, Angelique
dc.contributor.authorHAMMEL, Pascal
dc.contributor.authorLECAILLE, Cedric
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBUREAU, Mathilde
dc.contributor.authorPERRIER, Marine
dc.contributor.authorBOTSEN, Damien
dc.contributor.authorBOURGEOIS, Vincent
dc.contributor.authorTAIEB, Julien
dc.contributor.authorAUCLIN, Edouard
dc.date.accessioned2023-03-07T16:42:37Z
dc.date.available2023-03-07T16:42:37Z
dc.date.issued2022
dc.identifier.issn0020-7136en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172207
dc.description.abstractEnAfter failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR + PR + SD) and safety. We included 681 patients from 36 centers, 326 and 355 in the aflibercept and bevacizumab groups, respectively. Median age was 64.2 years and 45.2% of patients were men. Most patients had RAS-mutated tumors (80.8%) and synchronous metastases (85.7%). After a median follow up of 31.2 months, median OS was 13.0 months (95% CI: 11.3-14.7) and 10.4 months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P < .0001). Median PFS was 6.0 months (95% CI: 5.4-6.5) and 5.1 months (95% CI: 4.3-5.6) (P < .0001). After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P = .0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab.
dc.language.isoENen_US
dc.subject.enaflibercept
dc.subject.enbevacizumab
dc.subject.enchemotherapy
dc.subject.enmetastatic colorectal cancer
dc.title.enFOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/ijc.34166en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35833561en_US
bordeaux.journalInternational Journal of Canceren_US
bordeaux.page1978-1988en_US
bordeaux.volume151en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=International%20Journal%20of%20Cancer&amp;rft.date=2022&amp;rft.volume=151&amp;rft.issue=11&amp;rft.spage=1978-1988&amp;rft.epage=1978-1988&amp;rft.eissn=0020-7136&amp;rft.issn=0020-7136&amp;rft.au=TORREGROSA,%20Cecile&amp;PERNOT,%20Simon&amp;VAFLARD,%20Pauline&amp;PERRET,%20Audrey&amp;TOURNIGAND,%20Christophe&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée